Belarus’ pharmaceutical company NatiVita (Vitebsk Oblast) intends to branch out into the Syrian and Iraqi markets in 2019-2020.
The Syrian and Iraqi Health Ministries have inspected the manufacturing complex of NatiVita for compliance with the international requirements of Good Manufacturing Practices (GMP). The inspectors highly appreciated NatiVita’s pharmaceutical quality system and its technological capacity. The final report states that the company’s products are recommended for registration without a repeat GMP inspection.
“Thus, our products can easily reach the Syrian and Iraqi markets. We plan to start exporting drugs to Syria in the second half of 2019 and to Iraq at the beginning of 2020,” the specialists noted.
The company stressed that Syria and Iraq have great market potential. NatiVita intends to promote the entire line-up of anti-cancer drugs there. The NatiVita pharmaceutical company produces high-technology drugs. The company’s pharmaceutical products include capsules, tablets and injections which are used to treat cancer and other socially significant diseases. The company has registered 18 drugs that are used to treat cancer, multiple sclerosis, Hepatitis C.
The registration of nine more drugs, including ones against autoimmune disease, is underway. Four drugs that may change the ways to treat autoimmune, dermatological diseases and cancer are undergoing clinical trials.